癌症危重患者中普通肝素与低分子肝素及磺达肝癸钠用于静脉血栓栓塞药物预防的比较评价
该研究基于美国566家医院2010至2014年数据,纳入103798例癌症危重患者,经倾向性匹配比较低分子肝素与普通肝素预防静脉血栓栓塞的效果。低分子肝素未降低静脉血栓栓塞发生率,但与肺栓塞、显著出血及肝素诱导的血小板减少症发生率降低相关。
要点
- 低分子肝素预防未降低癌症危重患者院内静脉血栓栓塞发生率。
- 低分子肝素与肺栓塞、显著出血及肝素诱导的血小板减少症发生率降低相关。
- 非转移性实体瘤亚组中低分子肝素与静脉血栓栓塞及肺栓塞降低相关。
核心结论
- 与普通肝素相比,低分子肝素用于静脉血栓栓塞预防未降低癌症危重患者院内静脉血栓栓塞发生率,但与肺栓塞、临床重要出血事件及肝素诱导的血小板减少症发生率显著降低相关。
研究设计与样本
- 基于Premier数据库的倾向性匹配比较效果队列研究,纳入2010年1月1日至2014年12月31日期间美国566家医院中年龄18岁及以上、主要诊断为癌症、入住重症监护室且入院2天内接受静脉血栓栓塞预防的患者。
- 共纳入103798例患者,其中75321例(72.6%)接受低分子肝素,28477例(27.4%)接受普通肝素;倾向性分析按2:1匹配42343例低分子肝素患者与21218例普通肝素患者。
主要发现
- 总体而言,低分子肝素与静脉血栓栓塞发生率降低无关(5.32% vs 5.50%)。
- 低分子肝素预防与肺栓塞(0.70% vs 0.99%)、显著出血(13.3% vs 14.8%)及肝素诱导的血小板减少症(0.06% vs 0.19%)发生率降低相关。
- 在非转移性实体瘤中,低分子肝素与静脉血栓栓塞(4.27% vs 4.84%)及肺栓塞(0.47% vs 0.95%)降低相关。
关键数值与推荐
- 低分子肝素组静脉血栓栓塞发生率5.32%,普通肝素组5.50%。
- 低分子肝素组肺栓塞发生率0.70%,普通肝素组0.99%。
- 低分子肝素组显著出血发生率13.3%,普通肝素组14.8%。
- 低分子肝素组肝素诱导的血小板减少症发生率0.06%,普通肝素组0.19%。
- 非转移性实体瘤亚组中,低分子肝素组静脉血栓栓塞发生率4.27%,普通肝素组4.84%;肺栓塞发生率0.47% vs 0.95%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Critically ill cancer patients require pharmacologic prophylaxis for venous thromboembolism (VTE). Patients from 566 hospitals in the United States between 2010 and 2014 were included. Low-molecular-weight heparin (LMWH) prophylaxis was not associated in a reduction of VTE rates. LMWH prophylaxis was associated with a reduction in bleeding and heparin induced thrombocytopenia. SUMMARY: Background Critically ill patients with cancer are at increased risk of venous thromboembolism (VTE) from physical and cellular factors, requiring pharmacologic prophylaxis to reduce the risk of VTE. Objectives To assess whether low-molecular-weight heparin (LMWH) prophylaxis reduces in-hospital rates of VTE or improves clinical outcomes compared with unfractionated heparin (UFH) prophylaxis in critically ill patients with cancer. Methods We used a propensity-matched comparative-effectiveness cohort from the Premier Database. Patients aged 18 years or older with a primary diagnosis of cancer, intensive care unit admission and VTE prophylaxis within 2 days of admission between 1 January 2010 and 31 December 2014 were included. Patients were divided into LMWH or UFH prophylaxis groups. Results A total of 103 798 patients were included; 75 321 (72.6%) patients received LMWH and 28 477 (27.4%) patients received UFH. Propensity analysis matched (2 : 1) 42 343 LMWH patients and 21 218 UFH patients. Overall, LMWH was not associated with a decreased incidence of VTE (5.32% vs. 5.50%). LMWH prophylaxis was associated with a reduction in pulmonary embolism (0.70% vs. 0.99%), significant bleeding (13.3% vs. 14.8%) and heparin-induced thrombocytopenia (HIT) (0.06% vs. 0.19%). In non-metastatic solid disease, LMWH was associated with decreased VTE (4.27% vs. 4.84%) and PE (0.47% vs. 0.95%). Conclusions The use of an LMWH for VTE prophylaxis was not associated with a reduction in the incidence of in-hospital VTE as compared with UFH, but was associated with significant reductions in PE, clinically important bleeding events, and incidence of HIT in critically ill patients with cancer.
引用
- Van Matre ET, Reynolds PM, MacLaren R, et al. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer. J Thromb Haemost. 2018. PMID: 30347498. doi:10.1111/jth.14317
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。